Gloucester Pharmaceuticals’ Istodax® (romidepsin) Receives FDA Approval to Treat Cutaneous T-cell Lymphoma
I am pleased to announce that my partner and co-founder, Jay Mohr, Managing Director of Locust Walk Partners, recently achieved a professional milestone. Jay was founding CEO of Gloucester Pharmaceuticals and was responsible for diligencing and in-licensing Istodax® from Fujisawa (now Astellas).